These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32574205)

  • 1. Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfection.
    Herrera AL; Van Hove C; Hanson M; Dale JB; Tweten RK; Huber VC; Diel D; Chaussee MS
    PLoS One; 2020; 15(6):e0235139. PubMed ID: 32574205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination against the M protein of Streptococcus pyogenes prevents death after influenza virus: S. pyogenes super-infection.
    Klonoski JM; Hurtig HR; Juber BA; Schuneman MJ; Bickett TE; Svendsen JM; Burum B; Penfound TA; Sereda G; Dale JB; Chaussee MS; Huber VC
    Vaccine; 2014 Sep; 32(40):5241-9. PubMed ID: 25077423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenic mechanisms of invasive group A Streptococcus infections by influenza virus-group A Streptococcus superinfection.
    Okamoto S; Nagase S
    Microbiol Immunol; 2018 Mar; 62(3):141-149. PubMed ID: 29377225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Streptococcus pyogenes capsule is required for adhesion of bacteria to virus-infected alveolar epithelial cells and lethal bacterial-viral superinfection.
    Okamoto S; Kawabata S; Terao Y; Fujitaka H; Okuno Y; Hamada S
    Infect Immun; 2004 Oct; 72(10):6068-75. PubMed ID: 15385511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-chain variable fragment (scFv) targeting streptolysin O controls group A Streptococcus infection.
    Aikawa C; Kawashima K; Fukuzaki C; Nakakido M; Murase K; Nozawa T; Tsumoto K; Nakagawa I
    Biochem Biophys Res Commun; 2021 Aug; 566():177-183. PubMed ID: 34129965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus.
    Wozniak A; Scioscia N; García PC; Dale JB; Paillavil BA; Legarraga P; Salazar-Echegarai FJ; Bueno SM; Kalergis AM
    Microbiol Immunol; 2018 Jun; 62(6):395-404. PubMed ID: 29704396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Hypervariable region of Streptococcus pyogenes M protein escapes antibody attack by antigenic variation and weak immunogenicity.
    Lannergård J; Gustafsson MC; Waldemarsson J; Norrby-Teglund A; Stålhammar-Carlemalm M; Lindahl G
    Cell Host Microbe; 2011 Aug; 10(2):147-57. PubMed ID: 21843871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contributions of Influenza Virus Hemagglutinin and Host Immune Responses Toward the Severity of Influenza Virus: Streptococcus pyogenes Superinfections.
    Klonoski JM; Watson T; Bickett TE; Svendsen JM; Gau TJ; Britt A; Nelson JT; Schlenker EH; Chaussee MS; Rynda-Apple A; Huber VC
    Viral Immunol; 2018; 31(6):457-469. PubMed ID: 29870311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergent
    Odo CM; Vega LA; Mukherjee P; DebRoy S; Flores AR; Shelburne SA
    Infect Immun; 2024 Jul; 92(7):e0015224. PubMed ID: 38888310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies against a synthetic peptide of SagA neutralize the cytolytic activity of streptolysin S from group A streptococci.
    Dale JB; Chiang EY; Hasty DL; Courtney HS
    Infect Immun; 2002 Apr; 70(4):2166-70. PubMed ID: 11895983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular Group A
    Nozawa T; Iibushi J; Toh H; Minowa-Nozawa A; Murase K; Aikawa C; Nakagawa I
    mBio; 2021 Feb; 12(1):. PubMed ID: 33563838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enrichment of Antigen-Specific Class-Switched B Cells from Individuals Naturally Immunized by Infection with Group A Streptococcus.
    Lamb CL; Price E; Field KP; Dayton C; McIndoo ER; Katahira EJ; Stevens DL; Hobdey SE
    mSphere; 2019 Nov; 4(6):. PubMed ID: 31694896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar ability of FbaA with M protein to elicit protective immunity against group A streptococcus challenge in mice.
    Ma CQ; Li CH; Wang XR; Zeng RH; Yin XL; Feng HD; Wei L
    Cell Mol Immunol; 2009 Feb; 6(1):73-7. PubMed ID: 19254483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influenza enhances host susceptibility to non-pulmonary invasive
    Herrera AL; Potts R; Huber VC; Chaussee MS
    Virulence; 2023 Dec; 14(1):2265063. PubMed ID: 37772916
    [No Abstract]   [Full Text] [Related]  

  • 15. Antibodies to the conserved region of the M protein and a streptococcal superantigen cooperatively resolve toxic shock-like syndrome in HLA-humanized mice.
    Pandey M; Calcutt A; Ozberk V; Chen Z; Croxen M; Powell J; Langshaw E; Mills JL; Jen FE; McCluskey J; Robson J; Tyrrell GJ; Good MF
    Sci Adv; 2019 Sep; 5(9):eaax3013. PubMed ID: 31517054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Streptococcus pyogenes fibronectin/tenascin-binding protein PrtF.2 contributes to virulence in an influenza superinfection.
    Herrera AL; Faal H; Moss D; Addengast L; Fanta L; Eyster K; Huber VC; Chaussee MS
    Sci Rep; 2018 Aug; 8(1):12126. PubMed ID: 30108238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with formalin-inactivated influenza vaccine protects mice against lethal influenza Streptococcus pyogenes superinfection.
    Okamoto S; Kawabata S; Fujitaka H; Uehira T; Okuno Y; Hamada S
    Vaccine; 2004 Jul; 22(21-22):2887-93. PubMed ID: 15246625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The streptococcal M protein: a highly versatile molecule.
    Smeesters PR; McMillan DJ; Sriprakash KS
    Trends Microbiol; 2010 Jun; 18(6):275-82. PubMed ID: 20347595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human polyspecific immunoglobulin attenuates group A streptococcal virulence factor activity and reduces disease severity in a murine necrotizing fasciitis model.
    Tarnutzer A; Andreoni F; Keller N; Zürcher C; Norrby-Teglund A; Schüpbach RA; Zinkernagel AS
    Clin Microbiol Infect; 2019 Apr; 25(4):512.e7-512.e13. PubMed ID: 30025835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune response against M protein-conserved region peptides from prevalent group A Streptococcus in a North Indian population.
    Gupta VK; Sekhar S; Dhanda V; Toor D; Kumar R; Chakraborti A
    J Microbiol Immunol Infect; 2016 Jun; 49(3):352-8. PubMed ID: 25087198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.